Kobayashi Pharmaceutical Weighs Buyout Offer Above ¥500B From CVC, Nippon Sangyo Suishin Kiko

A take-private of this size would mark a notable shift for a Japanese consumer-healthcare name, where domestic ownership has long been the norm. The involvement of two private-equity buyers, rather than a strategic acquirer, points to appetite for stable cash-generating brands in Japan's healthcare space. What matters is whether the board engages seriously or treats the approach as opportunistic; no decision or timeline has been disclosed, so the open question is whether this becomes a formal process or fades.